Organization | GMP BIO Co., LTD.

GMP BIO Co., LTD. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Gwangju Korea, Republic of (2000)

Organization Overview

First Clinical Trial

2007

NCT03973099

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Director | GMP BIO Co., LTD.

Active Ingredients

Drugs in Phase 3 Trials (1)

house dust mite allergen (1 trial)

Drugs in Phase 2 Trials (11)

64cu-sar-bbn (1 trial)

autologous regulatory t cells (1 trial)

bemiparin (Ivor) (1 trial)

cd19 car-t cells (1 trial)

fluorouracil (efudex) (2 trials)

irinotecan (Camptosar) (2 trials)

leucovorin (2 trials)

lutetium dotatate lu-177 (Lutathera) (1 trial)

nivolumab (opdivo) (1 trial)

oxaliplatin (eloxatin) (2 trials)

vaccine pvcs n+c+r (1 trial)

Drugs in Phase 1 Trials (1)

xenon-129 (Xenoview) (1 trial)

Drugs in Other Trials (3)

cannabidiol (Epidiolex) (1 trial)

nelumbinis semen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Alzheimer Disease (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Neuroendocrine Tumors (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial APIs: 16